Publication List

PUBLICATIONS LIST:

 

1. Do Transferrin Levels Predict Haemodialysis Adequacy in Patients with End-Stage Renal Disease?
Tarantino G, Vinciguerra M, Ragosta A, Citro V, Conforti P, Salvati G, Sorrentino A, Barretta L, Balsano C, Capone D.
Nutrients. 2019 May 20;11(5). pii: E1123. doi: 10.3390/nu11051123.
I.F. (2017) 4.196


2. Oleuropein Induces AMPK-Dependent Autophagy in NAFLD Mice, Regardless of the Gender.
Porcu C, Sideri S, Martini M, Cocomazzi A, Galli A, Tarantino G, Balsano C.
Int J Mol Sci. 2018 Dec 8;19(12). pii: E3948. doi: 10.3390/ijms19123948.
I.F. (2017) 3.687


3. Is copper a new target to counteract the progression of chronic diseases?
Balsano C, Porcu C, Sideri S.
Metallomics, 2018 Oct 19; doi: 10.1039/c8mt00219c.
I.F. (2017) 3.975


4. Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study.
Raparelli V, Pastori D, Pignataro SF, Vestri AR, Pignatelli P, Cangemi R, Proietti M, Davì G, Hiatt WR, Lip GYH, Corazza GR, Perticone F, Violi F, Basili S; ARAPACIS Study Collaborators.
Intern Emerg Med., 2018 Aug; 13(5):651-660 doi: 10.1007/s11739-018-1922-y.
I.F. (2017) 2.340


5. Copper/MYC interplay: a dangerous relationship in hepatocellular carcinoma
Porcu C,Antonucci L,Barbaro B,Illi B,Nasi S, Martini M, Licata A, Miele L, Grieco A, Balsano C.
Oncotarget. 2018; 9:9325-9343.
I.F. (2017) 5.168


6. Prediction of carotid intima-media thickness in obese patients with low prevalence of comorbidities by serum copper bioavaliability
Tarantino G, Porcu C, Arciello M, Andreozzi P, Balsano C.
J Gastroenterol Hepatol, 2018 6 Feb; doi: 10.1111/jgh.14104.
I.F. (2017) 3.452


7. Evaluation of tolerance to ambulatory blood pressure monitoring: Analysis of dipping profile in a large cohort of hypertensive patients.
Iannucci G, Petramala L, La Torre G, Barbaro B, Balsano C, Curatulo PG, Amadei F, Paroli M, Concistrè A, Letizia C.
Medicine, 2017 Dec; 96(50) pii: E9162 doi: 10.1097/MD.0000000000009162.
IF 1.803


8. Non-Alcoholic Fatty Liver Disease and Nutritional Implications: Special Focus on Copper.
Antonucci L, Porcu C, Iannucci G, Balsano C, Barbaro B.
Nutrients, 2017 Oct 18; 9(10) pii: E1137 doi: 10.3390/nu9101137.
IF 3.550


9. Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.
Gnani D, Romito I, Artuso S, Chierici M, De Stefanis C, Panera N, Crudele A, Ceccarelli S, Carcarino E, D'Oria V, Porru M, Giorda E, Ferrari K, Miele L, Villa E, Balsano C, Pasini D, Furlanello C, Locatelli F, Nobili V, Rota R, Leonetti C, Alisi A.
Cell Death Differ., 2017 May; 24(5):889-902. doi: 10.1038/cdd.2017.34.
IF 8.339


10. Small heterodimer partner 1 directly interacts with NS5A viral protein and has a key role in HCV related liver cell transformation.
Conti B, Porcu C, Viscomi C, Minutolo A, Costantini S, Corazzari M, Iannucci G, Barbaro B, Balsano C.
Oncotarget., 2016 Dec 20; 7(51):84575-84586. doi: 10.18632/oncotarget.12144.
IF 5.008


11. AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF).
Women in Hepatology Group.; Italian Association for the Study of the Liver (AISF).
Dig Liver Dis., 2016 Aug; 48(8):860-8. doi: 10.1016/j.dld.2016.04.009
IF 2.719


12. Core domain mutant Y220C of p53 protein has a key role in copper homeostasis in case of free fatty acids overload.
Arciello M, Longo A, Viscomi C, Capo C, Angeloni A, Rossi L, Balsano C.
Biometals, 2015 Dec; 28(6):1017–29 /s10534-015-9886-0
IF 2.134


13. Protective Effect of the Y220C Mutant p53 Against Steatosis: Good News?
Gori M, Barbaro B, Arciello M, Maggio R, Viscomi C, Longo A, Balsano C.
J Cell Physiol., 2015 Jun; 230(6):1400. doi: 10.1002/jcp.24874.
IF 4.155


14. Normocaloric low cholesterol diet modulates Th17/Treg balance in patients with chronic hepatitis C virus infection.
Maggio R, Viscomi C, Andreozzi P, D'Ettorre G, Viscogliosi G, Barbaro B, Gori M, Vullo V, Balsano C.
PLoS One, 2014 Dec 22; 9(12):e112346. doi: 10.1371/journal.pone.0112346.
IF 3.534


15. Effects of the olive-derived polyphenol oleuropein on human health.
Barbaro B, Toietta G, Maggio R, Arciello M, Tarocchi M, Galli A, Balsano C.
Int J Mol Sci., 2014 Oct 14; 15(10):18508-24. doi: 10.3390/ijms151018508.
IF 2.339


16. Could monitoring normotensives delay progression to hypertension?
Iannucci G, Scarpellini E, Balsano C, Paroli M, Leone G, Giannoni MF.
Eur Rev Med Pharmacol Sci., 2014 Jun; 18(11):1680-1.
IF 0.988


17. Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease.
Alisi A, Nobili V, Ceccarelli S, Panera N, De Stefanis C, De Vito R, Vitali R, Bedogni G, Balsano C, Cucchiara S, Stronati L.
Expert Rev Mol Diagn., 2014 Jul; 14(6):763-71. doi: 10.1586/14737159.2014.928205.
IF 2.93


18. Lymphocytes as liver damage mirror of hcv related adipogenesis Deregulation.
Minutolo A, Conti B, Viscomi C, Grelli S, Labbadia G, Balsano C.
PLoS One, 2014 Mar 21; 9(3):e92343. doi: 10.1371/journal.pone.0092343.
IF 3.534


19. MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma.
Gori M, Arciello M, Balsano C.
Biomed Res Int., 2014; 2014:741465. doi: 10.1155/2014/741465.
IF 2.134


20. Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy.
Violi F, Daví G, Hiatt W, Lip GY, Corazza GR, Perticone F, Proietti M, Pignatelli P, Vestri AR, Basili S; ARAPACIS Study Investigators.
J Am Coll Cardiol, 2013 Dec 10; 62(23):2255-6. doi: 10.1016/j.jacc.2013.07.035.
IF 14.086


21. Exocycilic DNA adducts in a Murine Model of Non-Alcoholic Steatohepatitis.
Peluso MME, Munnia A, Tarocchi M, Arciello M, Balsano C, Giese RW, Galli A.
J Carcinog Mutagen., 2013 Oct 18; S3:003. doi: 10.4172/2157-2518.S3-003
IF 3.60


22. Breath tests for the assessment of the orocecal transit time.
Scarpellini E, Abenavoli L, Balsano C, Gabrielli M, Luzza F, Tack J.
Eur Rev Med Pharmacol Sci., 2013 Dec; 17 Suppl 2:39-44.
IF 0.988


23. Mitochondrial dysfunctions and altered metals homeostasis: new weapons to counteract HCV-related oxidative stress.
Arciello M, Gori M, Balsano C.
Oxid Med Cell Longev., 2013;2013:971024. doi: 10.1155/2013/971024
IF 3.393


24. Office normotensives with a minimal augmentation of intima-med thickness of common carotid arteries: really normotensives?
Iannucci G, Balsano C, Paroli M, Scarpellini E, Leone G, Giannoni MF.
Eur Rev Med Pharmacol Sci., 2013 Dec; 17(23):3164-8.
IF 1.093


25. Environmental Pollution: A Tangible Risk for NAFLD Pathogenesis.
Arciello M, Gori M, Maggio R, Barbaro B, Tarocchi M, Galli A, Balsano C.
Int J Mol Sci., 2013 Nov 7; 14(11):22052-66. doi: 10.3390/ijms141122052.
IF 2.464


26. Probiotics in non-alcoholic fatty liver disease: which and when.
Abenavoli L, Scarpellini E, Rouabhia S, Balsano C, Luzza F.
Ann Hepatol., 2013 May-Jun; 12(3):357-63.
IF 1.671


27. Are Hedgehog and Wnt/β-catenin pathways involved in hepatitis C virus-mediated EMT?
Conti B, Minutolo A, Arciello M, Balsano C.
J Hepatol., 2013 Mar; 58(3):636-7. doi: 10.1016/j.jhep.2012.10.033.
IF 9.858


28. Focal adhesion kinase (FAK) mediates the induction of pro-oncogenic and fibrogenic phenotypes in hepatitis C virus (HCV)-infected cells.
Alisi A, Arciello M, Petrini S, Conti B, Missale G, Balsano C.
PLoS One, 2012; 7(8):e44147. doi: 10.1371/journal.pone.0044147.
IF 3.730


29. Hepatitis C in the elderly: a multicentre cross-sectional study by the Italian Association for the Study of the Liver.
Gramenzi A, Conti F, Cammà C, Grieco A, Picciotto A, Furlan C, Romagno D, Costa P, Rendina M, Ancarani F, Chiaramonte M, Verucchi G, Craxì A, Bernardi M, Andreone P; AISF HepaElder Study Group.
Dig Liver Dis., 2012 Aug; 44(8):674-80. doi: 10.1016/j.dld.2012.03.009.
IF 3.162


30. Paradoxical prosteatotic effect of hedgehog dignaling inhibition under condition of steatosis.
Gori M, Barbaro B, Arciello M, Balsano C.
Hepatology, 2012 Oct; 56(4):1587-8. doi: 10.1002/hep.25729.
 
31. Cardiovascular and cerebrovascular events pre and post earthquake of April 6th 2009:the Abruzzo's experience.
Sofia S, Melone A, Manzoli L, De Ciantis P, Varrato E, Di Filippo R, Vittorini P, Balsano C.
Am J Hypertens, 2012 May; 25(5):556-60. doi: 10.1038/ajh.2012.4.
IF 3.665


32. Inverse correlation between plasma oxysterol and LDL-cholesterol levels in hepatitis C virus- infected patients.
Arciello M, Petta S, Leoni V, Iannucci G, Labbadia G, Sofia S, Camma C, Craxi A, Balsano C.
Digt Liver Dis., 2012 Mar; 44(3):245-50. doi: 10.1016/j.dld.2011.10.022
IF 3.162


33. Hepatitis C virus (HCV) therapeutics: editing enzymes promising therapeutics targets?
Alisi A, Tomaselli S, Balsano C, Gallo A.
Hepatology, 2011 Aug; 54(2):742. doi: 10.1002/hep.24409.
IF 11.665


34. Effect of treatment with polyunsatured fatty acid on HCV- or diet induced fatty liver.

Comparcola D, Nobili V, Alisi A, Balsano C.
J Hepatol., 2011 Jun; 54(6):1325-6. doi: 10.1016/j.jhep.2011.01.019.
IF 9.264


35. The Activation of endotoxin/toll-like receptor4 pathway: the way to go from non-alcoholic steatohepatitis up to hepatocellular carcinoma.
Alisi A, Panera N, Balsano C, Nobili V.
Hepatology, 2011 Mar; 53(3):1069. doi: 10.1002/hep.24003
IF 11.665


36. Hepatitis C virus and alcohol: same mitotic targets but different signalling pathways.
Alisi A, Ghidinelli M, Zerbini A, Missale G, Balsano C.
J Hepatol., 2011 May; 54(5):956-63. doi: 10.1016/j.jhep.2010.08.016.
IF 9.264


37. Regarding epithelial mesenchimal transition induced by Hepatitis C virus core protein in cholangiocarcinoma.

Balsano C, Conti B, Arciello M.
Ann Surg Oncol., 2011 Mar; 18(3):896. doi: 10.1245/s10434-010-1212-z
IF 4.166


38. Functions and therapeutic value of Focal Adhesion Kinase signaling during hepatocellular carcinoma development and progression.
Alisi A, Balsano C.
Hepatology, 2010 Mar; 51(3):1092-3. doi: 10.1002/hep.23415
IF 11.665


39. 7-ketocholesterol and 5,6-secosterol modulate differently the stress-activated mitogen-activated protein kinases (MAPKs) in liver cells.
Anticoli S, Arciello M, Mancinetti A, De Martinis M, Ginaldi L, Iuliano L, Balsano C.
J Cell Physiol., 2010 Mar; 222(3):586-95. doi: 10.1002/jcp.21972.
IF 3.986


40. Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study.
Gramenzi A, Cursaro C, Margotti M, Balsano C, Spaziani A, Anticoli S, Loggi E, Salerno M, Galli S, Furlini G, Bernardi M, Andreone P.
World J Gastroenterol., 2009 Dec 21;1 5(47):5946-52
IF 2.092


41. Antioxidant Effects of Natural Bioactive Compounds.
Balsano C, Alisi A.
Curr Pharm Des. 2009;15(26):3063-73.
IF 4.414


42. La cultura e' il futuro di ogni Nazione.
Balsano C.
Analysis, 2009 Jun.
IF 3.272


43. Liver fibrosis and therapeutic strategies: the goal for improving metabolism.
Balsano C, Alisi A, Nobili V.
Curr Drug Targ., 2009 Jun; 10(6):505-12. doi: 10.2174/138945009788488459.
IF 3.932


44. Viral Hepatitis B: Established and Emerging Therapies.
Balsano C, Alisi A.
Curr Med Chem., 2008; 15(9):930-9.
IF 4.944


45. Recent advances in antiviral agents: established and innovative therapies for viral hepatitis.
Balsano C.
Mini Rev Med Chem., 2008 Apr; 8(4):307-18.
IF 3.06


46. Involvement of PI3K in HCV-related lymphoproliferative disorders.
Alisi A, Giannini C, Spaziani A, Caini P, Zignego AL, Balsano C.
J Cell Physiol., 2008 Feb; 214(2):396-404. doi:10.1002/jcp.21211
IF 3.643


47. PKR is a novel functional direct player that coordinates skeletal muscle differentiation via p38MAPK/AKT pathways.
Alisi A, Spaziani A, Anticoli S, Ghidinelli M, Balsano C.
Cell signal., 2008 Mar; 20(3):534-42. doi: 10.1016/j.cellsig.2007.11.006.
IF 4.147


48. Enhancing the Efficacy of Hepatocellular Carcinoma Chemotherapeutics with Natural Anticancer Agents.
Alisi A, Balsano C.
Nutr Rev., 2007 Dec; 65(12 Pt 1):550-3.
IF 2.937


49. Hepatitis C virus (HCV): an RNA virus with a pro-oncogenic potential.
Balsano C, Alisi A.
Dig Liver Dis, 2007 Sep; 39 Suppl 1:S46-51. doi: 10.1016/S1590-8658(07)80010-7
IF 2.00


50. Hepatits C virus core protein enhances B lymphocyte proliferation.
Alisi A, Giannini C, Spaziani A, Anticoli S, Caini P, Zignego AL, Balsano C.
Dig Liver Dis., 2007 Sep; 39 Suppl 1:S72-5. doi: 10.1016/S1590-8658(07)80015-6.
IF 2.00


51. Role of p38MAPK and PKR in HCV core-dependent nuclear delocalization of cyclin B1.
Spaziani A, Alisi A, Sanna D, Balsano C.
J Biol Chem., 2006 Apr 21; 281(16):10983-9.
IF 5.854


52. HCV related transformation and new therapeutic strategies: an update.
Balsano C, Alisi A.
Curr Cancer Ther Rev., 2006; 2(1), doi: 10.2174/157339406775471830.
IF 0.80


53. Thr 446 phosphorylation of PKR by HCV core protein deregulates G2/M phase in HCC cells.
Alisi A, Mele R, Spaziani A, Tavolaro S, Palescandolo E, Balsano C.
J Cell Physiol., 2005 Oct; 205(1):25-31.
IF 4.362


54. Physical and functional interaction between HCV core protein and the different p73 isoforms.
Alisi A, Giambartolomei S, Cupelli F, Merlo P, Fontemaggi G, Spaziani A, Balsano C.
Oncogene, 2003 May 1; 22(17):2573-80.
IF 6.495


55. Differential regulation of E2F1 apoptotic target genes in response to DNA damage.
Pediconi N, Ianari A, Costanzo A, Belloni L, Gallo R, Cimino L. Porcellini A, Screpanti I, Balsano C, Alesse E, Gulino A, Levrero M.
Nat Cell Biol.,2003 Jun; 5(6):552-8.
IF 20.268


56. p73 is regulated by phosphorylation at the G2/M transition.
Fulco M, Costanzo A, Merlo P, Mangiacasale R, Strano S, Blandino G, Balsano C, Lavia P, Levrero M.
J Biol Chem., 2003 Dec 5; 278(49):49196-202.
IF 6.482


57. DN-p73 is activated after DNA damage in a p53-dependent manner to regulate p53-induced cell cycle arrest.
Vossio S, Palescandolo E, Pediconi N, Moretti F, Balsano C, Levrero M, Costanzo A.
Oncogene, 2002 May 23; 21(23):3796-803.
IF 6.737


58. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes.
Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole PA, Fontemaggi G, Fanciulli M, Schiltz L, Blandino G, Balsano C, Levrero M.
Mol Cell., 2002 Jan; 9(1):175-86.
IF 16.611


59. Prevalence and genomic variability of transfusion transmitted virus in Italian cryptogenic chronic liver disease and and healty blood donors.
Artini M, Almerighi C, Cariani E, Rossini A, Levrero M, Balsano C.
Dig. Liver Dis, 2002 Aug;34(8):570-6.
IF 0.696


60. Sustained activation of Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the hepatitis C virus (HCV) core protein.
Giambartolomei S, Covone F, Levrero M, Balsano C.
Oncogene, 2001 May 3; 20(20):2606-10.
IF 7.43


61. Nonsteroidal anti-inflammatory drug metabolism potentiates interferon alfa signaling by increasing STAT1 phosphorylation.
Giambartolomei S, Artini M, Almerighi C, Moavero SM, Levrero M, Balsano C.
Hepatology, 1999 Aug; 30(2):510-6.
IF 7.344


62. Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with a type 2 autoimmune hepatitis.
Pensati L, Costanzo A, Ianni A, Accapezzato D, Iorio R, Natoli G, Nisini R, Almerighi C, Balsano C, Vajro P, Vegnente A, Levrero M.
Gastroenterology, 1997 Oct; 113(4):1384-9.
IF 10.250


63. The hepatitis B virus X gene induces p53 mediated programmed cell death.
Chirillo P, Pagano S, Natoli G, Puri PL, Burgio VL, Balsano C, Levrero M.
Proc Natl Acad Sci USA, 1997 Jul 22; 94(15):8162-7.
IF 9.04


64. MyoD prevents cyclinA/cdk2 containing E2F complexes formation in terminally differentiated myocytes.
Puri PL, Balsano C, Burgio VL, Chirillo P, Natoli G, Ricci L, Mattei E, Graessmann A, Levrero M.
Oncogene, 1997 Mar 13; 14(10):1171-84.
IF 6.772


65. Uncoupling of p21 induction and MyoD activation results in the failure of irreversible cell cycle arrest in doxorubicin-treated myocytes.
Puri PL, Medaglia S, Cimino L, Maselli C, Germani A, De Marzio E, Levrero M, Balsano C.
J Cell Biochem., 1997 Jul 1; 66(1):27-36.
IF 2.686


66. p300 is required for MyoD dependent cell cycle arrest and muscle specific gene transcription.
Puri PL, Avantaggiati ML, Balsano C, Sang N, Graessmann A, Giordano A, Levrero M.
EMBO J., 1997 Jan 15; 16(2):369-83.
IF 12.643


67. Tumor Necrosis Factor (TNF) Receptor 1 signaling downsteam of TNF receptor-associated factor 2.
Natoli G, Costanzo A, Moretti F, Fulco M, Balsano C, Levrero M.
J Biol Chem., 1997 Oct 17; 272(42):26079-82.
IF 6.963


68. Terapia dell'epatite da virus C. Trattamenti convenzionali e non.
Balsano C, Giambartolomei S, Artini M, Almerighi CG.
Gastroenterol., 1997; 2 n.3, 130-137.
IF 10.250


69. Activation of SAPK/JNK by TNF Receptor 1 through a noncytotoxic TRAF2-dependent pathway.
Natoli G, Costanzo A, Ianni A, Templeton DJ, Woodgett JR, Balsano C, Levrero M.
Science, 1997 Jan 10; 275(5297):200-3.
IF 24.676


70. Elevated serum levels of 90K/MAC-2BP predicts unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients.
Artini M, Natoli G, Tinari N, Costanzo A, Marinelli R, Balsano C, Porcari P, Angelucci D, D'Egidio M, Levrero M, Iacobelli S.
J Hepatol., 1996 Aug; 25(2):212-7.
IF 3.235


71. Hepatitis B virus pX activates NF-kB-dependent transcription through a Raf-independent pathway.
Chirillo P, Falco M, Puri PL, Artini M, Balsano C, Levrero M, Natoli G.
J Virology, 1996 Jan; 70(1):641-6.
IF 6.194


72. Infection of circulating and liver infiltrating T cells by hepatitis C virus of different subtypes.

Artini M, Nisini R, Missale G, Costanzo A, Accapezzato D, Balsano C, Barnaba V, Levrero M.
Viral Immunol., 1995; 8(2):63-73.
IF 1.00


73. Resistance to Fas-mediated apoptosis in human hepatoma cells.
Natoli G, Ianni A, Costanzo A, De Petrillo G, Ilari I, Chirillo P, Balsano C, Levrero M.
Oncogene,1995 Sep 21; 11(6):1157-64.
IF 7.991


74. Reactive oxygen intermediates mediate angiotensin II-induced c-Jun/c-Fos heterodimer DNA binding activity and proliferative hypertrofic responses in myogenic cells.
Puri PL, Avantaggiati ML, Burgio VL, Chirillo P, Collepardo D, Natoli G, Balsano C, Levrero M.
J Biol Chem., 1995 Sep 22; 270(38):22129-34.
IF 7.385


75. Modulation of intracellular signal transduction pathways by the hepatitis B virus transactivator pX.
Natoli G, Avantaggiati ML, Chirillo P, De Marzio E, Collepardo D, Falco M, Balsano C, Levrero M.
J Hepatol., 1995; 22(1 Suppl):14-20.
IF 2.776


76. Reactive oxygen intermediates (ROIs) are involved in the intracellular transduction of angiotensin II signal in C2C12 cells.
Puri PL, Avantaggiati ML, Burgio VL, Chirillo P, Collepardo D, Natoli G, Balsano C, Levrero M.
Ann NY Acad. Sci., 1995 Mar 27; 752:394-405.
IF 0.868


77. Ras- and Raf-dependent activation of c-jun transcriptional activity by the hepatitis B virus transactivator pX.
Natoli G, Avantaggiati ML, Chirillo P, Puri PL, Ianni A, Balsano C, Levrero M.
Oncogene ,1994 Oct; 9(10):2837-43.
IF 7.387


78. Selective expansion of cytotoxic T lymphocytes with a CD4+CD56+ surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with Hepatitis B virus.
Barnaba V, Franco A, Paroli M, Benvenuto R, De Petrillo G, Burgio VL, Santillo I, Balsano C, Bonavita MS, Cappelli G, Colizzi V, Curtona G, Ferrarini M.
J Immunol., 1994 Mar 15; 152(6):3074-87.
IF 7.383


79. Hepatitis B virus X gene product acts as a transactivator in vivo.
Balsano C, Billet O, Bennoun M, Cavard C, Zider A, Grimber G, Natoli G, Briand P, Levrero M.
J Hepatol., 1994 Jul; 21(1):103-9.
IF 3.154


80. Induction of the DNA-binding activity of c-jun/c-fos heterodimers by the hepatitis B virus transactivator pX.
Natoli G, Avantaggiati ML, Chirillo P, Costanzo A, Artini M, Balsano C, Levrero M.
Mol Cell Biol., 1994 Feb; 14(2):989-98.
IF 10.195


81. Normalization of depressed natural killer activity after interferon-alfa therapy is associated with a low frequency of relapse in patients with chronic hepatitis C.
Bonavita MS, Franco A, Paroli M, Santilio I, Benvenuto R, De Petrillo G, Levrero M, Perrone A, Balsano C, Barnaba V.
Int J Tissue React., 1993; 15(1):11-6.
IF 0.393


82. The Hepatitis B virus (HBV) pX transactivates the c-fos promoter through multiple cis-acting elements.
Avantaggiati ML, Natoli G, Balsano C, Chirillo P, Artini M, De Marzio E, Collepardo D, Levrero M.
Oncogene, 1993 Jun; 8(6):1567-74.
IF 6.991

83. Characterization of the hepatitis B virus transactivators: a possible direct role of the virus in the development of hepatocellular carcinoma.
Levrero M, Balsano C, Avantaggiati ML, Natoli G, Chirillo P, De Marzio E, Collepardo D, Costanzo A.
J Surg Oncol. Suppl., 1993; 3:34-36.
IF 0.450


84. Detection of replicative intermediates of viral RNA in peripheral blood mononuclear cells from chronic hepatitis C virus carriers.
Artini M, Natoli G, Avantaggiati ML, Balsano C, Chirillo P, Costanzo A, Bonavita MS, Levrero M.
Arch Virol. Suppl., 1993; 8:23-29.
IF 1.379


85. The hepatitis B virus X gene product transactivates the HIV-LTR in vivo.
Balsano C, Billet O, Bennoun M, Cavard C, Zider A, Grimber G, Natoli G, Briand P, Levrero M.
Arch Virol. Suppl., 1993; 8:63-71.
IF 1.379


86. Characterization of the hepatitis B Virus preS/S region encoded transcriptional transactivator.
Natoli G, Avantaggiati ML, Balsano C, De Marzio E, Collepardo D, Elfassi E, Levrero M.
Virology, 1992 Apr; 187(2):663-70.
IF 4.412


87. The hepatitis B virus X protein transactivation of c-fos and c-myc proto-oncogenes is mediated by multiple transcription factors.
Avantaggiati ML, Balsano C, Natoli G, De Marzio E, Will H, Elfassi E, Levrero M.
Arch Virol. Suppl., 1992; 4:57-61.
IF 1.666


88. Recombinant Immunoblot assay for hepatitis C virus antibody in chronic hepatitis.
Taliani G, Badolato MC, Lecce R, De Bac C, De Marzio E, Balsano C, Artini M, Levrero M.
Arch. Virol. Suppl., 1992; 4:232-233.
IF 1.666


89. A second-generation hepatitis C virus confirmatory test for chronic hepatitis B virus Infection.
Taliani G, Lecce R, Badolato MC, De Bac C, De Marzio E, Balsano C, Artini M, Levrero M.
J Infect Dis. , 1992 Jan; 165(1):180-1.
IF 5.499


90. The hepatitis B virus X protein transactivation of c-fos and c-myc proto-oncogenes is mediated by multiple transcription factors.
Avantaggiati ML, Balsano C, Natoli G, De Marzio E, Will H, Elfassi E, Levrero M.
Arch Virol. Suppl., 1992; 4:57-61.
IF 1.666


91. Truncated pre-S/S proteins transactivate multiple target sequences.
Natoli G, Balsano C, Avantaggiati ML, De Marzio E, Artini M, Collepardo D, Elfassi E, Levrero M.
Arch. Virol. Suppl., 1992; 4:65-69.
IF 1.666


92. Significance of anti-HBx antibodies in hepatitis B virus infection.
Levrero M, Stemler M, Pasquinelli C, Alberti A, Jean-Jean O, Franco A, Balsano C, Diop D, Brechot C, Melegari M, Villa E, Barnaba V, Perricaudet M, Will H.
Hepatology, 1991 Jan; 13(1):143-9.
IF 4.107


93. Full-lengh and truncated versions of the hepatitis B virus (HBV) X protein (pX) transactivate the cmyc protooncogene at the transcriptional level.
Balsano C.,. Avantaggiati ML, Natoli G, De Marzio E, Will H, Perricaudet M, Levrero M.
Biochem Biophys Res Commun., 1991 May 15; 176(3):985-92.
IF 3.803


94. Hepatitis B virus and hepatocellular carcinoma: a possible role for the viral transactivators.

Levrero M, Balsano C, Avantaggiati ML, Natoli G, De Marzio E, Will H.

Ital J Gastroenterol. 23, 576-583, 1991.
IF 0.664


95. Antibodies to hepatitis C virus in patients with hepatocellular carcinoma.
Levrero M, Tagger A, Balsano C, De Marzio E, Avantaggiati ML, Natoli G, Diop D, Villa E, Diodati G, Alberti A.
J Hepatol., 1991 Jan; 12(1):60-3.
IF 2.673


96. Defective and non defective adenovirus vectors for expressing foreign genes in vitro and in vivo.
Levrero M, Barnaba V, Manteca S, Ballay A, Balsano C, Avantaggiati ML, Natoli G, Skellekens H, Tiollais P, Perricaudet M.
Gene, 1991 May 30; 101(2):195-202.
IF 3.064


97. Hepatitis B virus X protein transactivates the long terminal repeats of human immunodeficiency virus types 1 and 2.
Levrero M, Balsano C, Natoli G, Avantaggiati ML, Elfassi E.
J Virol., 1990 Jun; 64(6):3082-3086.
IF 5.92


98. Hepatitis B virus (HBV) X gene expression in human cells and anti-HBx antibodies detection in chronic HBV infection.
Levrero M, Jean-Jean O, Balsano C, Will H, Perricaudet M.
Virology, 1990 Jan; 174(1):299-304.
IF 3.076


99. Liver derived T cell clones in autoimmune chronic active hepatitis: accessory cell function of hepatocytes expressing class II major hystocompatibility complex molecules.
Franco A, Barnaba V, Ruberti G, Benvenuto R, Balsano C, Musca A.
Clin Immunol Immunopathol., 1990 Mar; 54(3):382-94.
IF 2.124


100. Recognition of hepatitis B virus envelope proteins by liver-infiltrating T lymphocytes in chronic HBV infection.
Barnaba V, Franco A, Alberti A, Balsano C, Benvenuto R, Balsano F.
J Immunol.,1989 Oct 15; 143(8):2650-5.
IF 6.883


101. Expression of class I and II major histocompatibility complex antigens on human hepatocytes.
Franco A, Barnaba V, Natali PG, Balsano C, Musca A, Balsano F.
Hepatology, 1988 May-Jun;8(3):449-54.
IF 5.302

PUBLICATIONS WITHOUT I.F.

• Pathogenesis of hepatocellular carcinoma: new ideas for a targeted therapy.
Arciello M, Balsano C.
Hot Topics in Viral Hepatitis. Women in hepatology 2nd ed. 2013; 27 Doi:10.4147/HTV-132727

• Chronic viral hepatitis: its characteristics and management.
Brunetto MR, Balsano C, Burra P, Cariani E, Taliani G, Villa E.
Hot Topics in Viral Hepatitis. 7, 2011.

• La steatoepatite non alcolica (NASH). Cenni diagnostici e terapeutici.
Balsano C, Mici E.
Il Caduceo, 2006.

• Occult hepatitis B virus infection.
Raimondo G, Balsano C, Craxi A, Farinati F, Levrero M, Mondelli M, Pollicino T, Squadrito G,
Tiribelli C.
Dig Liver Dis., 2000 Dec;32(9):822-6.

• The molecular basis of myocardial hyperthrophy.
Puri PL, Natoli G, Avantaggiati ML, Balsano C, De Marzio P, Levrero M.
Ann Ital Med Int. 1994; 9:160-165.

• Ingegneria genetica e nuovi vaccini contro l'epatite B.
Levrero M, Natoli G, Avantaggiati ML.
Attualita' in Medicina Interna,1991; 5.

• La tecnica di amplificazione enzimatica del DNA (PCR) nella diagnostica dell'infezione da CMV.
Mancini C, Curcio S, Padula C, Avantaggiati ML, Balsano C, Lorino G, Carattoli A, Levrero M. Microbiologia Medica, 1990; 3(5).

• Ingegneria genetica e nuovi vaccini contro l'epatite B.
Balsano C, Natoli G, Avantaggiati ML, Levrero M.
Attualita' in Medicina , 1990; 5.

• La biologia molecolare del virus B dell'epatite.
Levrero M, Balsano C, Avantaggiati ML, Natoli G.
Attualita' in Medicina , 1990; 5.

• Effetto in vitro dell'alfa interferone e della timomodulina sull'attivita' natural killer in pazienti con AIDS related complex.
Paroli M, Balsano C, Valesini G, Biffoni M, Perrone A, Barnaba V.
Annali di Med. Interna, 1988; 3:39-44.

• Autoimmunita' epatica.
Barnaba V, Franco A, Ruberti G, Balsano C.
O.I.C. Medical Press., 1987:265.

BOOK

Oxidative stress, dysregulation of cell homeostasis and induction of cell trasformation
Editor: Balsano C, Research Signpost 37/661 (2).

Robot Therapy in Pediatric Emergency: Impact of Integrated Approach for Collaborative Patients
Rossi S, Di Giacomo D, Balsano C.

Olistic City: un paradigma possibile
Balsano C, Costantini S, De Gasperis G, Placidi G, Stilo G.

CHAPTERS ON BOOKS

• What is oxidative stress?
Balsano C, Victor VM, Costanzo A.
(2008), Introduction, Research Signpost, 37/661 (2), Fort P.O., Trivandrum-695 023, Kerala, India

• Redox status alterations and metabolic disorders.
Alisi A, Balsano C.
Chapter 5, Research Signpost, 37/661 (2)

• Role of oxidative stress in the pathogenesis of cancer
Balsano C, Alisi A.
(2008) Chapter 7, Research Signpost, 37/661 (2), Fort P.O.,

• Molecular basis of HCC.
Levrero M, Chirillo P, Balsano C, Natoli G.
Cap. 3° del vol. Epatocarcinoma, ed. Poletto. 1996.

• Role of oxidative stress in the pathogenesis of cancer Reactive oxygen intermediates (ROIs) are involved in the intracellular transduction of angiotensin II signal in C2C12 cells.
Puri PL, Avantaggiati ML, Burgio VL, Chirillo P, Collepardo D, Natoli G, Balsano C, Levrero M.
In: Cardiac Growth and Regeneration Ann. N. Y. Acad. Sci. Vol. 752, p. 394 (1995).

• La Medicina D'Emergenza Oggi. Capitolo
Le basi molecolari dell'adattamento cardiaco ai sovraccarichi di lavoro.
Levrero M, De Marzio P, Avantaggiati ML, Natoli G, Balsano C.
Vol. II 93° Congresso della SIMI. 1992.

• Transactivation of fos and myc protoncogenes by both full length and truncated versions of the HBV-X protein.
Levrero M, Avantaggiati ML, Natoli G, Balsano C, De Marzio E, Elfassi E, Will H.
B.M Hollinger ed; Viral Hepatitis 1990, Alan R. Liss Inc. 572,1990.

• Comparative analysis of transactivation by HBV-X, adenovirus E1A and HIV tat proteins.C.
Balsano C, Levrero M, Chaigne-Crescenzo C, Pillot J, Elfassi E.
B.M Hollinger ed; Viral Hepatitis 1990, Alan R. Liss Inc. 173, 1990.

Contatti